SOLICITATION NOTICE
B -- Serum estradiol and androstanediol glucuronide levels (STEED study)
- Notice Date
- 6/16/2008
- Notice Type
- Presolicitation
- NAICS
- 541690
— Other Scientific and Technical Consulting Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-80098-NG
- Archive Date
- 7/16/2008
- Point of Contact
- Ashley L. Virts, , Malinda L Holdcraft,, Phone: (301) 402-4509
- E-Mail Address
-
virtsa@mail.nih.gov, holdcram@exchange.nih.gov
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI) plans to procure on a sole source basis, Serum estradiol and androstanediol glucuronide levels among participants in the study of testicular germ cell tumors (the STEED study) with Boston Children’s Hospital; Department of Laboratory Medicine; Clinical and Epidemiologic Research Laboratory; Boston, Massachusetts 02115. The services herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13.106-(b) (1). The North American Industry Classification System Code is 541690 the business size standard is 6.5 M employees. The objective of this project is to determine levels of estradiol and androstanediol glucuronide (AAG) in the serum of the cases and controls in the STEED testicular germ cell tumor study, and to provide support for the measurement of estradiol in 1400 serum samples necessary to complete the project objective. The period of performance for this procurement is 12 months from the date of award. The NCI Division of Cancer Epidemiology and Genetics has conducted a case-control study of testicular germ cell tumors (the STEED study) among U.S. military servicemen. A unique feature of the study is that pre-diagnostic serum samples are available from the study participants. These samples have enabled the examination of several important hypotheses, including those related to pesticide exposure and insulin-like growth factor levels. Another key hypothesis is whether men who develop testicular germ cell tumors (TGCT) are predisposed because they have aberrant hormone levels prior to the development of disease. To examine this hypothesis, the study proposed to examine levels of both pituitary (luteinizing hormone, follicle-stimulating hormone) and steroid (testosterone, estradiol, sex-hormone binding globulin) hormones. Thus far, levels of luteinizing hormone and follicle-stimulating hormone have been determined. Levels of sex-hormone binding globulin and total testosterone are currently being measured. The final hormones of interest are estradiol and androstanediol glucuronide (AAG). The original expectation was that both hormones would be measured in the same endocrine laboratory that has measured the other hormones. At this point, there is only 200µL of serum left in each sample, so conventional estradiol assays can not be run. Boston Children’s Hospital – Department of Laboratory Medicine has developed an electrochemiluminescence immunoassay that can determine estradiol and AAG in a very small volume, 200µL, of serum. Using this assay would permit the STEED study to examine the prestated hypothesis of determining whether aberrant estradiol levels were associated with the development of testicular germ cell tumors. There is no other source known to the NCi that has a laboratory that can perform this assay using a small amount serum. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the researcher to determine if the party can meet this requirement. One (1) original and one (1) copy of the capability statement must be received in the contracting office by 11:00 a.m. ET on July 1, 2008. All questions must be in writing and can be faxed to 301-402-4513 or sent via email to Malinda Holdcraft: holdcram@exchange.nih.gov. It is the vendor’s responsibility to ensure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractor must have valid, updated registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Application (ORCA). Please reference NCI-80098-NG on all correspondence.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=514b4cf30b6371011db72e1e8ffbb4de&tab=core&_cview=1)
- Record
- SN01594222-W 20080618/080616215925-514b4cf30b6371011db72e1e8ffbb4de (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |